SEC Tracker
Get the app

Spyre Therapeutics SYRE

Spyre Therapeutics raises $350M

Form
8-K
Filed
Importance
Routine
  1. Entered underwriting agreement with Jefferies, TD Securities, Leerink, and Stifel
  2. Offering 4,117,648 shares at $85 each
  3. Gross proceeds expected to be $350M
  4. Plans to use funds for R&D and infrastructure

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Spyre Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Novavax NVAX public float $1.0B, Jun 30, 2025
  4. Harrow HROW public float $1.0B, Jun 30, 2025
  5. Aurinia Pharmaceuticals AUPH public float $1.0B, Jun 30, 2025